WallStSmart

Elanco Animal Health (ELAN)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 203% more annual revenue ($14.30B vs $4.71B). ELAN leads profitability with a -4.9% profit margin vs -24.6%. VTRS appears more attractively valued with a PEG of 0.14. ELAN earns a higher WallStSmart Score of 51/100 (C-).

ELAN

Buy

51

out of 100

Grade: C-

Growth: 6.7Profit: 3.0Value: 4.0Quality: 5.3
Piotroski: 4/9Altman Z: 0.90

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.80

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ELAN2 strengths · Avg: 9.0/10
EPS GrowthGrowth
116.7%10/10

Earnings expanding 116.7% YoY

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

ELAN4 concerns · Avg: 2.3/10
Operating MarginProfitability
2.3%3/10

Operating margin of 2.3%

PEG RatioValuation
4.112/10

Expensive relative to growth rate

Return on EquityProfitability
-3.7%2/10

ROE of -3.7% — below average capital efficiency

Altman Z-ScoreHealth
0.902/10

Distress zone — elevated risk

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-21.1%2/10

ROE of -21.1% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-24.6%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : ELAN

The strongest argument for ELAN centers on EPS Growth, Price/Book. Revenue growth of 12.2% demonstrates continued momentum.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : ELAN

The primary concerns for ELAN are Operating Margin, PEG Ratio, Return on Equity.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

ELAN carries more volatility with a beta of 1.89 — expect wider price swings.

ELAN is growing revenue faster at 12.2% — sustainability is the question.

VTRS generates stronger free cash flow (551M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ELAN scores higher overall (51/100 vs 50/100) and 12.2% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Elanco Animal Health

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets products for pets and farm animals. The company is headquartered in Greenfield, Indiana.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?